Article thumbnail

Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas.

By Myung-Ju Ahn, Se-Jin Jang, Yong-Wook Park, Jung-Hye Choi, Ho-Suk Oh, Chul-Burm Lee, Hong-Kyu Paik and Chan-Kum Park


Vascular endothelial growth factor (VEGF) is known to play a key role in tumor angiogenesis. The tumor-suppressor gene p53 has been thought to regulate VEGF. We investigated the effect of VEGF on esophageal carcinoma and the correlation between VEGF and p53. Tissue samples were taken from 81 patients with esophageal carcinoma after surgery. VEGF and p53 expressions were examined by immunohistochemical staining. Microvessels in the tumor stained for CD34 antigen were also counted. VEGF and p53 expressions were observed in 51.3% (41/80) and 51.9% (41/79), respectively. The microvessel density was 70.9+/-6.7 (mean+/-SE) in VEGF-positive group and 68.7+/-5.1 in VEGF-negative group. However, no correlation was noted between VEGF and p53 expression. Whereas the tumor size, nodal status, depth of invasions, and tumor stage were associated with poor overall survival, VEGF expression or p53 expression was not. These results indicate that VEGF and p53 are highly expressed in esophageal carcinomas. Since the VEGF expression is not correlated with the p53 expression, microvessel density or clinicopathological findings, further studies with other angiogenic molecules are needed to determine the role in esophageal carcinomas

Topics: Research Article
Publisher: Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1995). Angiogenesis and breast cancer metastasis. Lancet
  2. (1997). Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study.
  3. (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.
  4. (1999). Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus. Hepato-Gastroenterol
  5. (1998). In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.
  6. (1986). Interaction between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metastas
  7. (1993). Intratumoral microvessel density and p53 protein; correlation with metastasis in head and neck squamous cell carcinoma.
  8. (1989). Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived follicular stellate cells.
  9. (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev
  10. (1994). Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Oncogene
  11. (1996). New perspectives in clinical oncology from angiogenesis research.
  12. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.
  13. (1999). Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology.
  14. (1996). Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer
  15. (1994). Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas.
  16. (1996). Reciprocal paracrine interactions between tumor cells and endothelial cells; the angiogenesis progression hypothesis.
  17. (1995). Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.
  18. (1992). Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis.
  19. (1998). Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res
  20. (1995). Tsolkas l, Sukhatme VP. Wild type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res
  21. (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma.
  22. (1997). Tumor angiogenesis and prognosis. Histopathology
  23. (1995). Tumor angiogenesis as a predictor of recurrence in gastric carcinoma.
  24. (1995). Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol
  25. (1995). Tumor angiogenesis in breast cancer; its importance as prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat
  26. (2000). Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate
  27. (2000). Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol
  28. (1997). Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer
  29. (2000). Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of esophagus. Clin Cancer Res
  30. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science
  31. (1998). Vascular enumeration as a significant prognosticator for invasive breast carcinoma.